On December 20th, WUXI BIO announced that it has reached a research service cooperation agreement with Hangzhou Dohi Biotechnology Co., Ltd. and Aadi Bioscience to support Aadi's development of three next-generation antibody-drug conjugates (ADCs) that are in the preclinical stage. According to the terms of the agreement, Aadi will pay WUXI BIO and Dohi Biotechnology an upfront payment of 44 million USD, up to 0.265 billion USD in development milestone payments, and 540 million USD in commercial milestone payments, as well as a single-digit percentage of sales royalties.
药明生物和多禧生物与Aadi Bioscience就三款创新ADC达成研究服务合作
WUXI BIO and Dohi Biotechnology have reached a research service collaboration with Aadi Bioscience for three innovative ADCs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th